Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug436 | BAT2020 Wiki | 0.58 |
| drug3973 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001997 | Bronchopulmonary Dysplasia NIH | 0.58 |
| D008595 | Menorrhagia NIH | 0.58 |
| D006929 | Hyperaldosteronism NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D054559 | Hyperphosphatemia NIH | 0.58 |
| D004314 | Down Syndrome NIH | 0.58 |
| D000309 | Adrenal Insufficiency NIH | 0.58 |
| D007008 | Hypokalemia NIH | 0.58 |
| D014552 | Urinary Tract Infections NIH | 0.41 |
| D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.29 |
| D006470 | Hemorrhage NIH | 0.29 |
| D020141 | Hemostatic Disorders NIH | 0.15 |
| D001778 | Blood Coagulation Disorders NIH | 0.15 |
| D006973 | Hypertension NIH | 0.12 |
| D007249 | Inflammation NIH | 0.10 |
| D004194 | Disease NIH | 0.09 |
| D013577 | Syndrome NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002905 | Hyperphosphatemia HPO | 0.58 |
| HP:0002900 | Hypokalemia HPO | 0.58 |
| HP:0000846 | Adrenal insufficiency HPO | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000132 | Menorrhagia HPO | 0.58 |
| HP:0000859 | Hyperaldosteronism HPO | 0.58 |
| HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.29 |
| HP:0001928 | Abnormality of coagulation HPO | 0.15 |
| HP:0000822 | Hypertension HPO | 0.12 |
Navigate: Correlations HPO
There are 3 clinical trials
The purpose of this study is to investigate the infectious etiology of Kawasaki disease (KD); a prospective household and case control study for Kawasaki disease will be done. The investigators will enroll Kawasaki disease cases who have at least five of the following manifestations: 1. fever for over 5 days 2. neck lymphadenopathy 3. lip fissure and/or strawberry tongue 4. skin rash 5. nonpurulent bulbar conjunctivitis 6. palm/sole erythema and induration followed by desquamation, or coronary artery aneurysm with less than 5 of the above manifestations (atypical Kawasaki disease) The KD cases will receive virological (virus isolation from the blood, throat swabs and rectal swabs or stool, gene chip for possible viruses from stored RNA and DNA), bacterial (blood, throat swabs and stool: bacterial culture and stored strain for further toxin or superantigen detection), and serological (Mycoplasma pneumoniae, Chlamydiae pneumoniae, ASLO, HHV6, EV71, peptide library approach for auto-antibody or pathogen-related antibody, stored serum for further workup) workup. Stored DNA from the blood will also be performed.
Description: The mean age of the 226 KD cases was 2.07 years, and the male to female ratio was 1.43 (133 boys to 93 girls). Their mean fever duration was 7.5 days with a mean peak temperature of 39.7°C. In addition to the typical symptoms of fever, neck lymphadenopathy, lip fissure and/or strawberry tongue, skin rash, nonpurulent bulbar conjunctivitis, palm/sole erythema, and induration followed by periungual desquamation, these KD cases also exhibited cough (69%), rhinorrhea (58%), and diarrhea (45%). Cases of KD had a significantly higher positive rate of viral isolation in comparison with the control group (7.5% vs. 2.2%, p = 0.02). Compared with the control group, cases of KD were more likely to have overall positive rates of viral PCR (50.4% vs. 16.4%, p < 0.001) and for various viruses including enterovirus (16.8% vs. 4.4%, p < 0.001), adenovirus (8.0% vs. 1.8%, p = 0.007), human rhinovirus (26.5% vs. 9.7%, p < 0.001), and coronavirus (7.1% vs. 0.9%, p = 0.003).
Measure: Viral infections associated with Kawasaki disease Time: 2014/3The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Beginning in mid-March 2020, pediatricians in communities in Western Europe, the UK, and the Eastern U.S. that had been severely affected by the Covid-19 pandemic noted an increased number of children presenting with fever and evidence of severe inflammation who required admission to intensive care. The syndrome was branded by the CDC in the U.S. as Multisystem Inflammatory Syndrome in Children (MIS-C). The most severely affected children presented with heart failure leading to shock and the absence of significant pulmonary disease. The clinical presentation in these patients shared many features with Kawasaki disease (KD), a self-limited pediatric vasculitis that can result in coronary artery aneurysms.The inflammatory markers, however, were much higher even than KD shock syndrome, a variant of KD presenting with distributive shock and requiring inotropic and vasoactive support in the ICU. Some patients were polymerase chain reaction (PCR)+ for SARS-CoV-2 while most were virus-negative but had detectable antibody suggesting that MIS-C was an immune-mediated reaction to antecedent exposure to the virus. While patients were being diagnosed with shock and MIS-C, children with a milder version of MIS-C that shared many features of KD were being diagnosed in these same regions.
Description: Collection of clinical data and patient samples from children with MIS-C and KD to understand the relationship between these two conditions.
Measure: Collection of clinical data and patient samples from children with MIS-C and KD to Time: We will collect demographic and clinical data on all KD patients at participating sites throughout the 8-month study period.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports